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Bridging the evidence-to-practice gap: a
stepped-wedge cluster randomized
controlled trial evaluating practice
facilitation as a strategy to accelerate
translation of a multi-level adherence
intervention into safety net practices
Antoinette Schoenthaler1* , Franzenith De La Calle1, Amanda Soto1, Derrel Barrett1, Jocelyn Cruz1, Leydi Payano1,
Marina Rosado1, Samrachana Adhikari1, Gbenga Ogedegbe1 and Milagros Rosal2
Abstract
Background: Poor adherence to antihypertensive medications is a significant contributor to the racial gap in rates
of blood pressure (BP) control among Latino adults, as compared to Black and White adults. While multi-level
interventions (e.g., those aiming to influence practice, providers, and patients) have been efficacious in improving
medication adherence in underserved patients with uncontrolled hypertension, the translation of these
interventions into routine practice within “real world” safety-net primary care settings has been inadequate and
slow. This study will fill this evidence-to-practice gap by evaluating the effectiveness of practice facilitation (PF) as a
practical and tailored strategy for implementing Advancing Medication Adherence for Latinos with Hypertension
through a Team-based Care Approach (ALTA), a multi-level approach to improving medication adherence and BP
control in 10 safety-net practices in New York that serve Latino patients.
Methods and design: We will conduct this study in two phases: (1) a pre-implementation phase where we will
refine the PF strategy, informed by the Consolidated Framework for Implementation Research, to facilitate the
implementation of ALTA into routine care at the practices; and (2) an implementation phase during which we will
evaluate, in a stepped-wedge cluster randomized controlled trial, the effect of the PF strategy on ALTA
implementation fidelity (primary outcome), as well as on clinical outcomes (secondary outcomes) at 12 months.
Implementation fidelity will be assessed using a mixed methods approach based on the five core dimensions
outlined by Proctor’s Implementation Outcomes Framework. Clinical outcome measures include BP control (defined
as BP< 130/80 mmHg) and medication adherence (assessed using the proportion of days covered via pharmacy
records).
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Discussion: The study protocol applies rigorous research methods to identify how implementation strategies such
as PF may work to expedite the translation process for implementing evidence-based approaches into routine care
at safety-net practices to improve health outcomes in Latino patients with hypertension, who suffer
disproportionately from poor BP control. By examining the barriers and facilitators that affect implementation, this
study will contribute knowledge that will increase the generalizability of its findings to other safety-net practices
and guide effective scale-up across primary care practices nationally.
Trial registration: ClinicalTrials.gov NCT03713515, date of registration: October 19, 2018.
Keywords: Hypertension, Medication adherence, Latino persons, Practice facilitation, Primary care
Contributions to the literature
 The impact of practice facilitation on the implementation of
evidence-based interventions to support hypertension man-
agement into safety-net practices remains largely untested.
 This study will identify how practice facilitation may work to
expedite the translation process for implementing evidence-
based multi-level interventions to improve health outcomes
in safety-net settings.
 This study will also address questions about individual and
practice-level factors likely to influence the implementation
of such approaches. Published reports often omit important
details about implementation fidelity (i.e., extent to which
system changes are implemented), what kind of training or
assistance practices need, and how these approaches fit
within the practice culture.
Background
Uncontrolled hypertension is one of the most prevalent
primary care diagnoses and the single most important
factor driving the high rates of cardiovascular-related
mortality and health care expenditures in the United
States (US) [1]. While recent national data show increas-
ing trends in the awareness and treatment of hyperten-
sion among individuals from all racial/ethnic groups,
disparities in blood pressure (BP) control persist. Among
Latino adults, rates of BP control are lower than among
non-Hispanic black and white adults (35%, 43%, and
48%, respectively) [2]. Rates of BP control are lowest
among Latino persons of Central American, South
American, Cuban, and Dominican descent [3]. These
statistics may be explained by the disproportionately
poorer adherence to antihypertensive medications
among Latino patients compared to Black and White pa-
tients [4–7]. Data from NHANES III showed that hyper-
tensive Latino adults reported the lowest levels of
adherence to their antihypertensive medications (67%)
compared to Black and White adults (77% for both racial
groups) [8]. Similar findings were documented in the
Health and Retirement Study, in which 53% of Latino
participants with hypertension reported adhering to anti-
hypertensive medications compared to 64% and 73% of
White and Black older adults [4]. In a recent national
survey, 32% of Latino adults reported being adherent to
cardiovascular medications, compared to 39% and 50%
of Black and White respondents [9].
Growing evidence shows that multi-level interventions
(i.e., those that aim to influence the patient, healthcare
providers, and clinic systems) can produce significant
improvements in patients’ medication adherence and
clinical outcomes [10, 11]. Our own work showed that a
multi-level intervention that included an office redesign
component built into the electronic health record (EHR;
i.e., to identify, refer, coach, document, and track pro-
gress of patients with uncontrolled hypertension), a pro-
vider support component consisting of shifting self-
management activities to clinic Medical Assistants
(MAs), and a patient engagement component consisting
of personalized health coaching by MAs significantly im-
proved self-reported medication adherence (78% vs.
72%, p = 0.02) compared to enhanced usual care in a
sample of Latino patients at a community health center
[12]. However, evidence-based interventions often take
up to 17 years to be translated into clinical practice [13],
especially in the context of under-resourced “safety-net”
practices, due to unique financial, administrative, and
patient challenges that slow the implementation of new
care innovations (e.g., patients have more complex
health issues, limited reimbursement for self-
management support) or can lead to significant disrup-
tions in practice workflow (e.g., limited clinical capacity
to meet demand for patient services) [14, 15].
Practice facilitation (PF) is one model for accelerating
the implementation of evidence-based interventions into
healthcare settings [16, 17]. Through PF, a specially
trained individual (facilitator) works with healthcare
teams to develop the skills to adapt and implement
evidence-based approaches into routine care (e.g., by
redesigning workflows to support team-based care) [18].
In contrast to single component (e.g., audit and feed-
back) and other multicomponent implementation
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strategies (e.g., Learning Collaborative), PF places em-
phasis on building organizational capacity to make
evidence-based systems changes that are tailored to the
practice context to achieve sustainable improvements in
system, provider and patient-level outcomes [17]. One
systematic review found that primary care practices that
used PF were 2.76 times more likely to implement
evidence-based strategies than usual care practices [19].
Several studies have found that the effects of PF were
sustained for as long as 1 year post intervention [20–22].
Despite the growing evidence of effectiveness of PF in
primary care, few studies have focused on understanding
“how to” facilitate the implementation of evidence-based
system-level approaches into routine practice within
safety-net primary care settings [17]. Thus, the impact of
PF on implementing evidence-based systems to support
hypertension management in safety-net practices re-
mains largely untested.
To address this gap in the evidence-base, this article
describes the design and methods that will be used in
the Advancing Medication Adherence for Latinos with
Hypertension through a Team-based Care Approach
(ALTA) trial, a multi-level approach to improving medi-
cation adherence and BP control. This cluster random-
ized trial will be conducted at ten safety-net practices in
New York and will focus on Latino patients given the




Using a mixed-methods approach, this study will be con-
ducted in two phases: (1) a pre-implementation phase
where we will refine the PF strategy, based on the Consoli-
dated Framework for Implementation Research (CFIR) [23]
to facilitate the implementation of ALTA; and (2) an imple-
mentation phase, guided by Proctor’s Implementation
Outcomes Framework (IOF) [24, 25]. The primary aim of
the implementation phase is to evaluate, in a stepped-
wedge cluster randomized trial, the level of implementation
fidelity (e.g., degree to which a program is delivered as
intended) of ALTA at 10 safety-net primary care practices
that serve Latino patients. The secondary aims are to com-
pare the effects of PF versus usual care (UC) on BP control
and medication adherence among Latino patients with un-
controlled hypertension who are non-adherent to their an-
tihypertensive medications followed in the practices. We
will also explore the potential moderating factors at the
healthcare system-, provider/staff-, and patient-levels (e.g.,
organizational capacity to change, evidence-based practice
attitudes) [26–30] that influence the level of implementa-
tion fidelity of ALTA at the practices.
As shown in Fig. 1, each participating practice will
start with the UC phase and are block-randomized to re-
ceive PF into four waves, with two sites per wave. The
sequence of randomization for each block is generated
by the study statistician and kept in sealed opaque enve-
lopes away from the study sites in accordance with
CONSORT guidelines.
The UC phase will be followed by the pre-
implementation phase of 6 months, during which facili-
tators will conduct a practice evaluation (e.g., workflow
analysis, environmental scan) based on CFIR, refine the
PF strategies that will be used in the implementation
phase, and train staff in the ALTA intervention. Follow-
ing this period, sites will implement ALTA with the as-
sistance of the PF for 12 months, with a 3-month follow-
up period for outcome assessment. This study was ap-
proved by the Institutional Review Board of the New
York University Langone Health (NYULH).
Study setting and participants
ALTA will be implemented as a standard of care at each
of the 10 safety-net primary care practices participating
Fig. 1 Stepped-wedge design of ALTA implementation
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in the trial. As such, study participants will include all
practice providers/staff who will implement ALTA and
patients seeking care at the practices. To address our
secondary aims, we will focus our analysis on the subset
of patients who identify as Latino adults (described
below).
A Clinic Hypertension Committee consisting of the Site
Directors, Director of the clinic Quality Improvement
Committee, Nurse Managers, Patient Service Coordinators,
Primary Care Providers, and Patient Advocates recruited
across the practices will provide input on recruitment and
retention strategies for the sites, providers/staff, and pa-
tients throughout the course of the trial.
Recruitment
Primary care practices
Primary care safety-net practices will be selected and
invited to participate with the assistance of Clinical
Leadership who oversees the practices and outreach
to the individual Site Directors. Practices will be eli-
gible for participation if they (1) have an Epic EHR,
(2) have used the EHR for at least 6 months, (3) have
no immediate future plans to participate in a
hypertension-related quality improvement initiative,
(4) be willing to sign a Memorandum of Understand-
ing and identify a practice champion to work with
study staff on all aspects of the project implementa-
tion, (5) and be located in New York.
Practice staff and providers
We will recruit approximately ten clinical (e.g., primary
care providers, nurses, medical assistants) and five non-
clinical staff per practice to complete the study measures
on the implementation of ALTA. A subset of these indi-
viduals will also be recruited to be part of the ALTA im-
plementation team for their practice. Practice clinical
and non-clinical staff will be recruited through study
team attendance at the monthly staff meetings, email
communications that describe the project including the
overarching goals and what is expected of participants,
and in-person meetings at the practices.
Patients
The analytic sample for the secondary aim will consist of
patients who meet the following eligibility criteria: (a)
identifies as Latino/a as documented in EHR codes; (b)
be ≥ 18 years of age; (c) have uncontrolled hypertension
defined using the 2017 guidelines for stage 1 [BP > 130–
139 or 80–89mmHg] and stage 2 [BP ≥ 140 or ≥ 90
mmHg] hypertension [31], as documented in the EHR
on at least two visits in the past year; and (d) have been
prescribed at least one antihypertensive medication and
are non-adherent to their medication defined as adher-
ence < 80% in the preceding 12 months, as determined
by prescription orders obtained from the EHR. Patients
will be excluded if they (a) currently participate in an-
other hypertension study, (b) have significant psychiatric
comorbidity or reports of substance abuse (as docu-
mented in the EHR), (c) are pregnant or planning to be-
come pregnant within 12 months, or (d) plan to
discontinue care at the practice within the next 12
months. As a multi-level study that will include the en-
tire health system, all potentially eligible patients will be
identified through a review of the EHR-embedded
hypertension registry.
Conceptual framework
The study uses two implementation science theoretical
frameworks—CFIR and Proctor’s IOF. A strength of
CFIR is the ability to tailor the framework to the specific
intervention design and practice context being studied
by exploring four major domains (intervention charac-
teristics, external environment [outer setting], inner
practice setting, and characteristics of individuals in-
volved) that affect effective implementation of evidence-
based practices [23, 32]. Proctor’s IOF guides in the
evaluation of distinct implementation outcomes (imple-
mentation fidelity) that serve as indicators of implemen-
tation success of evidence-based practices [25].
Achieving a high level of implementation fidelity is ne-
cessary to attribute desired changes in clinical outcomes
(e.g., improvements in BP control and medication adher-
ence) to the effectiveness of the intervention and not to
extraneous variables [33]. Diminished implementation fi-
delity is a primary reason why interventions conducted
in controlled academic clinical settings do not yield
similar results when translated to real-world primary
care practices [33, 34].
Our conceptual model (Fig. 2) illustrates the integration
of our theoretical frameworks. The model hypothesizes
that use of a tailored PF implementation strategy that tar-
gets the CFIR facilitators and barriers will result in a high
level of implementation fidelity of ALTA (primary out-
come) and that a higher proportion of patients will exhibit
both improved BP control and medication adherence (sec-
ondary outcomes) during the PF implementation phase as
compared to the UC phase. We will also explore the po-
tential practice and individual-level moderating factors
(e.g., organizational capacity to change, evidence-based
practice attitudes) that influence the level of implementa-
tion fidelity of ALTA at the practices.
Description of ALTA
ALTA is a multi-level approach to improving medication
adherence and BP control in primary care practices. It is
designed to build practice capacity to address the needs
of hypertensive patients by utilizing a team-based ap-
proach to delivering hypertension care. ALTA includes
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five key components, which are conducted by existing
members of the practice (Table 1): (1) Identify ALTA-
eligible patients using EHR hypertension registries; (2)
Refer ALTA patients to a clinic Health Coach using the
EHR; (3) Coach ALTA patients using a structured coun-
seling tool integrated into the EHR to identify patients’
treatment goals, asses their current level of BP control
and medication adherence, identify barriers and facilita-
tors to medication adherence, develop patient-centered
adherence goals and action plans, and use a structured
treatment algorithm to optimize patient antihypertensive
medication regimen; (4) Document brief progress notes
from the coaching session in the EHR to inform other
team members of the patient’s adherence status, action
plans, progress toward goals, and any changes to the an-
tihypertensive medication regimen; and (5) Monitor and
schedule follow-up sessions with ALTA patients in the
EHR.
Description of PF implementation strategy
Usual care (UC) phase
During the UC phase, patients at the sites will receive
standard hypertension care delivered by their primary
care providers.
Pre-implementation phase
Immediately following the UC phase and prior to the
implementation of ALTA, all practices will participate
in the pre-implementation phase for a period of 3
months. During the pre-implementation phase, facili-
tators will conduct a practice capacity assessment at
each practice, including the identification of barriers
and facilitators to the implementation of ALTA. This
CFIR-guided assessment includes utilizing qualitative
interviews, validated surveys, and environmental scans.
In accordance with CFIR, the assessment will explore
the (1) inner practice setting (e.g., leadership support,
Fig. 2 ALTA conceptual model




Identify • EHR registry to identify Latino patients with uncontrolled Hypertension and are prescribed antihypertensive medications
• Screen patients for medication non-adherence using a standardized adherence screening and document the result in the EHR
Refer • Send EHR alert to clinic Health Coach (e.g., RN, MA) about patient’s BP level and adherence status
Coach • Structured assessment of medication adherence
• Use of motivational interviewing to identify facilitators/barriers to adherence and discuss personalized strategies to improve
adherence behaviors
• Use of structured medication titration algorithm to optimize patient treatment regimen
• Use of teach back to ensure patient understanding of treatment plan
• Co-creation of culturally-relevant goals and action plans
Document • Structured documentation of coaching sessions in EHR to enable tracking patients’ progress over time
• EHR Documentation of individualized treatment plan, medication adherence goals, and action plan to guide future sessions and
share with primary care provider for clinic visits
Monitor • Consistent monitoring of patient progress through completion of and tracking follow-up sessions with ALTA patients
EHR electronic health record, MA Medical Assistant, ALTA Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach
Schoenthaler et al. Implementation Science Communications            (2021) 2:21 Page 5 of 14
organizational capacity), (2) external environment
(e.g., patient needs and resources, external resources
and incentives), (3) staff characteristics (e.g., self-
efficacy, knowledge, and beliefs about patient-centered
counseling), and (4) intervention characteristics (e.g.,
complexity).
An environmental scan is a structured needs assess-
ment that combines observational and survey data col-
lection methodologies to develop a robust understanding
of the internal conditions and external factors that affect
implementation [35–39]. In this study, the environmen-
tal scan will serve the dual purpose of (1) developing a
practice assessment to guide the refinement of the PF
strategies that will be tested in the implementation phase
and (2) giving the facilitators an opportunity to form re-
lationships with practice staff and develop a shared un-
derstanding of project roles and responsibilities. To
conduct the scan, facilitators will combine the CFIR ob-
servational tool with a structured workflow analysis and
survey questions that assess staffs’ perceptions about the
practice culture [40], beliefs about organizational change
[28], and self-efficacy to conduct health coaching ses-
sions [41]. Together, these data will be used to develop a
robust understanding of the facilitators and barriers to
implementation of ALTA at the practices.
Findings from the interviews and environmental
scan will be synthesized into a report and shared with
the Clinic Hypertension Committee. The Committee,
in partnership with the study team, will use this re-
port to tailor the PF strategy to the practice context
to overcome identified challenges to implementation
of ALTA into routine practice in the implementation
phase. During this period, the study team will also
hold a Kick-off Event at the practices that will in-
clude didactic and interactive sessions on topics such
as the ALTA model components, best practices for
implementing team-based models of care, defining
roles and responsibilities in interdisciplinary care
teams, developing effective interdisciplinary and
patient-centered communication skills, and a discus-
sion of the implementation and evaluation process.
The study team will use strategies to maximize at-
tendance of all clinical and non-clinical staff at the
Kick-off Event. These include creating a shared vision
for the project by working in partnership with prac-
tice leadership to develop workflows and strategies
that complement and bolster current quality improve-
ment initiatives for hypertension management; distrib-
uting incentives to practices and staff that recognize
their role as “quality improvement champions” and
show appreciation for their participation, and holding
listening sessions with physicians and nurses to
understand the unique needs and desires they have
for improving hypertension in their patients.
Implementation phase
PF consists of building trusting relationships, fostering
collaborative team-based problem solving, building ef-
fective communication, leveraging data and health infor-
mation technology (HIT) to drive improvement, and
establishing and sharing common goals between the fa-
cilitator and those engaged in making the change [42].
Through the PF strategy, facilitators are building prac-
tice’s skills and capacity to sustain workflows and care
processes needed for ALTA and to continue to learn,
monitor, and adapt it after the study has ended.
Our PF strategy is designed to stimulate specific, ac-
tionable steps that the practices can undertake to build a
foundation that supports the integration of all five com-
ponents of ALTA into primary care practices as routine
care. This will combine one-on-one onsite tailored facili-
tation with opportunities for shared learning across
practices through collaborative calls (Table 2).
The rationale for onsite visits is informed by expert
consensus that in-person visits are essential to establish
and maintain an effective working relationship between
sites and PFs [16]. PFs will coordinate meetings with
practices, assist them in setting performance goals, train
clinic staff in the key components of ALTA as well as in
quality improvement strategies for practice redesign
(e.g., workflow mapping), strategize on implementing
ALTA-related practice changes, assist teams in testing
workflow changes using the Plan-Do-Study-Act cycle,
and share best practices for implementing ALTA within
and across practices [16–18, 43]. A quality improvement
and implementation manual informed by these tasks will
be developed by the study team to drive the delivery of
the PF strategy and implementation of ALTA.
Each PF will be responsible for five practices and will
conduct a minimum of 13 site visits over the 12-month
implementation period. These design decisions (number
of site visits, ratio of facilitators to practices) are based
on a systematic review of PF research and our experi-
ence implementing similar studies [16, 43, 44].
Practice facilitator (PF) training and supervision
All PFs will have clinical and/or managerial experi-
ence in primary care settings and will have received
training through the HealthTeamWorks Quality Im-
provement Training program, which is based upon
AHRQ’s Practice Facilitation Handbook [18]. The
training covers four core competencies of PF: data
use to drive improvement, interpersonal skills, HIT
optimization, quality improvement, and change man-
agement methods [45]. In the first year of the project,
we will add curriculum components to meet the spe-
cific goals of this study (e.g., education on the up-
dated hypertension guidelines) as well as training
tailored to the specific ALTA components, including
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system changes that we propose to implement, and
data extraction from EHRs. The training will combine
didactic sessions and case-based learning and will in-
clude booster sessions. A PF Supervisor will hold
weekly meetings to help PFs (1) develop and maintain
relationships, (2) maintain effective boundaries to
allow the practice to build capacity, (3) acquire the
content knowledge needed for the PF strategy, (4)
monitor their progress through the implementation of
change concepts, (5) troubleshoot problems, and (6)
review their activity reports.
Evaluation
We will use a mixed methods approach to collect
process and clinical-related outcomes at the patient,
staff, and practice-levels to evaluate the implementation
of ALTA into routine care within the safety-net prac-
tices. The primary outcome is a degree of implementa-
tion fidelity measured at the practice and staff-levels.
Secondary outcomes at the patient-level will include BP
control and medication adherence. Implementation fi-
delity will be assessed on an ongoing basis throughout
the implementation phase. Study assessments for the
secondary clinical outcomes will be completed at base-
line visit and 12 months.
Primary outcome measure
Implementation fidelity Fidelity to ALTA will be de-
fined by five core dimensions, as defined by Proctor’s
IOF [25, 46]: (1) adherence to the program protocol, (2)
dose of the program delivered, (3) quality of program
delivery, (4) participant responsiveness, and (5) program
differentiation. Each of these dimensions will be assessed
using a structured tool developed for this study (Fig. 3)
and defined in the following manner:
Implementation adherence will be evaluated as the de-
gree to which the components of ALTA (e.g., identify,
refer, coach, document, monitor) were implemented as
intended, using data from checklists completed by the
facilitators as well as extracted from the EHR. Each
intervention component will be rated on a 3-point scale:
1 = the component was not implemented, as per proto-
col, 2 = the component was partially implemented, and
3 = the component was fully implemented and/or modi-
fied with permission, as per protocol. PFs will also
complete bimonthly narrative reports that summarize all
adaptations made to the components and what did/did
not work for each practice context.
Implementation dose will be evaluated as the extent to
which patients were exposed to ALTA. We will collect
Table 2 Practice facilitation (PF) strategies
ALTA component ALTA PF strategy
Identify • Assist clinic staff in identifying ALTA-eligible patient by using HYPERTENSION registries
• Assist clinic staff in utilizing the HYPERTENSION registry to identify ALTA-eligible patients
• Assist practices in optimizing the HYPERTENSION registry to simplify prioritization of HYPERTENSION patients that
can benefit from health coaching
Refer • Assist clinic staff in developing a referral workflow that supports referral to a health coach
• Assist clinic staff in referring ALTA-eligible patients to a health coach
Coach • Assist clinic staff in developing a health coaching session workflow that maximize the delivery of the intervention
by using the ALTA structured tool to:
o Reconcile HYPERTENSION medications and optimize treatment regimen using structured algorithm
o Assess patient’s treatment goals
o Assess medication adherence
o Identify adherence barriers and facilitators
o Develop goal/action plan for improved adherence
• Assist clinic staff in using patient-centered communication
Document • Assist clinic staff in documenting short progress notes with the patient’s HYPERTENSION treatment regimen,
adherence level, and adherence goal/action plan in the EHR to inform other team members of the patient’s
status
Monitor • Assist clinic staff in identifying opportunities for follow-up





Dashboards/reporting • Assist clinic staff in allocating resources for quality improvement activities and developing a reporting process to
assess fidelity
• Assist clinic staff in assessing quality improvement activities with HYPERTENSION management performance
dashboards
Establish operational systems • Assist clinic staff in optimizing EHR functionality to support adherence to ALTA interventions
• Assist clinic staff in identifying a workable HYPERTENSION workflow that includes the ALTA key drivers
• Assist staff to identify and resolve barriers to implementation fidelity
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data on utilization patterns of the different ALTA com-
ponents including the mean number of ALTA-eligible
patients identified in the registry and referred to a
Health Coach, health coaching sessions completed with
ALTA patients, entries in the EHR-embedded coaching
script, progress notes documented in the EHR and
shared with the care team, and follow-up sessions that
are scheduled and/or completed. System files will be ex-
tracted quarterly and will contain date and time stamps
as well as user logins for the tools used.
Implementation quality of each ALTA component will
be evaluated as the quality and content of data entry in
the hypertension registry, EHR-embedded coaching
script, progress notes, and follow-up scheduling. PFs will
rate the completeness of this form using a 3-point rating
scale (1, poor; 2, adequate; 3, high). A random 10% sam-
ple of counseling sessions by the clinic Health Coaches
will also be audiotaped and evaluated using the Health
Coaching Evaluation Checklist, as we have done in our
previous trials [47]. A fidelity score will be calculated as
the percentage of topics completed and how well they
were delivered (1, poor skill performance; 2, adequate
skill performance; 3, exemplary skill performance).
Participant responsiveness will be evaluated as patient
and practice staff/provider satisfaction with ALTA and
acceptability of practice changes with validated measures
(i.e., ECHO survey for patients and a modified survey for
staff/providers) [48, 49]. In addition, qualitative
interviews will be conducted with a random sample of
clinic staff (n = 30) and patients (n = 30) across the
practices to assess satisfaction with the intervention.
Program differentiation will be evaluated as the unique
features of ALTA that are distinguishable from other
programs at the sites. Throughout the study, facilitators
will catalog all initiatives that are occurring at the prac-
tices (as observed during site visits and/or reported by
the practice leadership). This will be used to quantify the
degree of overlap between the ALTA components and
other quality improvement initiatives at the sites (1, no
overlap; 2, some overlap; 3, significant overlap) as well as
isolate the unique features of ALTA that distinguish it
from those initiatives.
Secondary outcome measures
BP control will be defined as SBP < 130 and DBP < 90
mmHg [31]. BP control will be assessed using the mean
of the last two measurements recorded in the EHR dur-
ing each of the pre-intervention and post-intervention
study periods (baseline and 12months). BP readings will
be extracted electronically from patients’ EHR using the
centralized Clinical Research Data Management Core
(DataCore) group at NYULH. We will use the last two
recorded measures to reduce variability associated with
multiple BP measurements being taken by different
clinic staff. We will also explore the effect of PF on con-
tinuous BP reduction, defined as the mean change in
Fig. 3 Excerpt of structured tool to assess implementation fidelity
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systolic and diastolic BP based on the mean of the last
two recorded BP readings in the EHR during the pre-
and post-implementation periods.
Medication adherence will be assessed via pharmacy
refills obtained from prescription orders in the clinic
EHR using the proportion of days covered (PDC) metric.
The PDC is calculated as the total number of days cov-
ered by the medication divided by the number of days
between the first fill of the medication in the study
period and the end of the study period [50]. The PDC
accounts for non-persistence with medications by track-
ing medications during the study period despite early
discontinuation. We will count the days the patient was
covered by each of their prescribed antihypertensive
medications based on the prescription fill date and days
of supply [51]. If prescription refills for the same medi-
cation overlap, then we will adjust the prescription start
date to be the day after the previous fill has ended. Pa-
tients will be considered adherent if they fill ≥ 80% of
their antihypertensive medications over the 12months.
In addition, we will assess the extent of self-reported
medication non-adherence and reasons for non-
adherence using a survey developed by Voils and col-
leagues [52, 53].
Moderator measures
We will evaluate the potential moderating roles of prac-
tice- and provider/staff-level factors on implementation
fidelity of ALTA at the practices, administering mea-
sures at baseline. All measures will be administered to
clinical and nonclinical staff and administrative leader-
ship at the practices. Staff will be invited to complete the
measures via a broadcast email, which will contain a link
to a secure website (i.e., RedCap) that includes the con-
sent form and surveys. To maximize participation, staff
will receive a $25 gift card for completing the measures.
Adaptive reserve is defined as a practice’s ability to
make and sustain change and includes measures of fa-
cilitative leadership, relationship infrastructure, and cul-
ture of learning. Adaptive reserve will be assessed with
the 23-item scale developed for the National Demonstra-
tion Project Model of the Patient-Centered Medical
Home (α = 0.86) [54].
Implementation climate will be assessed with the 18-
item Implementation Climate Scale (ICS) that measures
shared perceptions of the policies, practices, procedures,
and behaviors that are expected, supported, and
rewarded to facilitate effective evidence-based practice
(EBP) implementation (α = 0.91) [29].
Implementation leadership will be assessed with the
12-item Implementation Leadership Scale (ILS), which
has excellent reliability, and convergent and discriminant
validity(α = 0.98) [27]. The ILS is comprised of four sub-
scales—proactive leadership (α = 0.95), knowledgeable
leadership (α = 0.96), supportive leadership (α = 0.95),
and perseverant leadership (α = 0.96).
Evidence-based practice (EBP) attitude scale is a 15-
item measure with four subscales that assess attitudes
toward the implementation of EBP as a function of the
perceived appeal of EBP, requirements to use EBP, pro-
vider openness, and perceived divergence between EBP
and usual care. Total scores (α = 0.76) represent global
attitudes toward adoption of EBP [26].
Covariate measures
Practice and provider/staff characteristics At baseline,
we will collect data on the number of full-time equiva-
lent staff, insurance payer mix, clinic volume, practice
structure, staff composition (e.g., number of providers,
nurses, MAs), use of HIT, current quality improvement
initiatives, and other current or planned programs at
each practice.
Patient sociodemographic and clinical characteristics
At baseline, we will extract data from the clinic EHR on
patient race and ethnicity, primary language spoken,
gender, insurance status, prescribed antihypertensive
medications, changes in antihypertensive medications,
weight, height, and the presence of other chronic
illnesses.
Statistical methods
Sample size and power analysis
Power calculations are based on the clinical outcome of
BP control using our prior work implementing the
ALTA model in a community-based clinic. In the former
trial, we found a significant improvement in attainment
of BP control at 6 months among patients randomized
to the intervention group compared to the UC group
(51% vs. 29%, p = 0.03). We expect a similar group dif-
ference of a 20% increase in BP control between the im-
plementation and UC phases in the current study.
Calculations of achieved power were estimated with a
stepped-wedge design using Power Analysis and Sample
Size (PASS) software program [55]. The power calcula-
tions show that we can recruit 10 sites and 700 patients
and have at least 80% power to detect a more conserva-
tive 15% difference in BP control between the UC and
implementation phases for intraclass correlation coeffi-
cients (ICCs) ranging from 0.01 to 0.05. Using our ori-
ginal estimate of a 20% difference in BP control, we
would have over 90% power to detect a difference be-
tween the UC and implementation phases with 10 sites
and 700 patients.
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Descriptive analysis
Baseline characteristics and outcomes will be summa-
rized descriptively and graphically; we will summarize
continuous variables with means, standard deviations,
medians, and ranges, and will summarize categorical var-
iables with frequency distributions.
Analysis of the primary aim
Qualitative analysis of implementation fidelity will com-
prise narrative reports (to assess program adherence),
audiotaped health coach sessions (to assess implementa-
tion quality), and semi-structured interviews with prac-
tice staff/providers and patients (to assess participant
responsiveness). Transcriptions of the narrative reports
and interviews will be coded using Dedoose software de-
signed for qualitative coding [56]. The coding scheme
will be developed by the study team and Clinic Hyper-
tension Committee to focus on key dimensions identi-
fied both a priori (i.e., from the interview protocols) and
those that emerge during site visits and interviews. Two
coders will independently code at least 10 transcripts,
after which we will establish the inter-rater reliability
[57]. If it is inadequate (Krippendorff’s alpha < 0.80), the
study team will work collaboratively to refine and/or
clarify the coding scheme and provide additional coder
training. Double coding will continue until adequate
inter-rater reliability is achieved. Coding the data will
allow us to fully describe the themes and the prevalence
of specific themes and sub-themes [46].
Quantitative analysis of implementation fidelity will
consist of descriptive statistics (i.e., mean, standard devi-
ations, frequencies) to provide documentation and de-
scriptions of the practices, implementation components,
and context. To describe levels of fidelity to ALTA, each
domain of fidelity (adherence, dose, quality, responsive-
ness, and differentiation) will be coded as described
above (i.e., scores will range from 1 to 3). To analyze
overall implementation fidelity, we will re-classify each
domain into low (score of 0), medium (score of 1), and
high levels (score of 2) of fidelity [58]. Overall imple-
mentation fidelity will be defined as the sum of all do-
mains and range from 0 to 10. To compare the level of
implementation fidelity across the practices, we will use
a least square means ANOVA model with weighting by
the number of patients seen in each practice within the
specified period.
Following the NIH Best Practices for mixed methods
research [59], we will construct a joint display [60] that
integrates the qualitative themes with the quantitative
data to create a composite measure of implementation
fidelity based on the five dimensions outlined above.
Should the data be divergent, we will assign higher cre-
dence to the qualitative data because it provides a richer
explanation about participants’ behaviors [59].
Analysis of the secondary aims
The effect of PF on BP control Our main clinical out-
come is the proportion of patients with adequate BP
control (< 130/80 mmHg) at 12 months in the imple-
mentation vs. UC phase. BP control will be treated as a
dichotomous outcome variable in this analysis; any pa-
tients with missing follow-up BP data will be assumed to
have inadequate BP control. To examine the difference
in BP control rates between the implementation and UC
phases, we will utilize a generalized linear mixed model
(GLMM) to assess the PF effect. A Poisson regression
model will be used to predict BP control specifying a
fixed effect for time, a fixed effect for treatment, and a
time by treatment interaction. Random effects will be
specified for person and practice to account for the clus-
tered nature of the dataset (observations within person
and people within practices). In exploratory analyses,
will examine the intervention effect on BP reduction at
12 months, treated as a continuous variable. An add-
itional sensitivity analysis will be conducted using
GLMM to evaluate the effect of PF on BP reduction. We
will test the treatment X time interactions in a random
effects linear regression model to determine the time-
specific differences BP reduction attributable to PF at
the end of the implementation phase.
Randomization of the stepped-wedge design should
obviate the need for adjustment, but in the case of im-
balanced in baseline covariates, these will be included as
necessary in adjusted analyses. All tests will be two-sided
with alpha = 0.05 for comparison between the imple-
mentation and UC phases. Maximum likelihood estima-
tion of mixed-effects models will be used to account for
missing data; in the context of a mixed-effects model,
this is equivalent to an assumption of data that are miss-
ing at random; we will conduct sensitivity analyses asses-
sing this assumption. We will also compare participants
with and without missing values with respect to baseline
and practice characteristics. If differential patterns
emerge, we will consider the use of multiple imputation
and/or inverse probability weighting to adjust for miss-
ing data. Analyses will be conducted using Stata, SAS,
and R.
Associations between rates of BP control and imple-
mentation fidelity will be evaluated using structural
equation modeling methods. We will estimate a path
model using maximum likelihood estimation to inves-
tigate relationships between BP control and imple-
mentation fidelity. Implementation fidelity will be
identified as individual and simultaneous predictors of
BP control. Practice-, staff-, and patient-level vari-
ables, which may influence the level of implementa-
tion fidelity, will also be included in the model. In
addition to the direct effects of each variable, the
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indirect effects from each variable to BP control via
mediator variables will be estimated as the product of
component direct effects and tested using boot-
strapped 95% confidence intervals. Structural equation
modeling analyses will be conducted using R and fit
indices will be evaluated to ensure model fit.
The effect of PF on medication adherence We will es-
timate similar models as BP control with PDC, calcu-
lated from available pharmacy records, as the outcome.
A GLMM model using maximum likelihood estimation
will be utilized to estimate the effect of PF on medica-
tion adherence with fixed effects specified for treatment
phase, time, and the treatment by time interaction. We
will apply any necessary transformations to the PDC
outcome to improve the approximation to normality and
explore alternative regression strategies, such as rank re-
gression and/or beta regression.
The effect of practice and individual-level
moderators on implementation fidelity of ALTA
Using the surveys described above, we will explore the
potential practice-, provider/staff-, and patient-level
moderators that may influence the association between
PF and implementation fidelity of ALTA. Potential mod-
erators will be evaluated using structural equation mod-
eling methods and fit indices will be evaluated for all
models to ensure adequate model fit.
Discussion
Poorly controlled hypertension is a major contributor to
the racial mortality gap in cardiovascular disease be-
tween persons from racial and ethnic minority groups
and White persons. National data indicate that Latino
patients with hypertension are more likely to have un-
controlled BP (72.4%) compared to White persons
(54.4%), despite a similar prevalence of hypertension in
both groups (19.5% in White and 17.8% in Latino per-
sons) [61]. Importantly, data from the NHLBI-sponsored
Hispanic Community Health Study/Study of Latinos
showed significant deficits in the treatment and control
of hypertension, with Latino men from Central Ameri-
can, South American, and Dominican ancestry (Latino
subgroups largely concentrated in the northeast US) ex-
periencing the lowest rates of BP control (12%, 25%, and
27%, respectively) compared to Mexican American men
(31%) [3, 62]. Similar patterns were seen in Latino
women. Inadequate blood pressure control due to poor
medication adherence may explain the worse outcomes
seen in Latino patients.
While research supports the efficacy of multi-level in-
terventions to improve medication adherence in Latino
patients [12, 63], there remains a large “translational
gap” in implementing these approaches into routine
practice in safety-net primary care practice settings. The
most common roadblocks to timely translation of
evidence-to-practice include trials being conducted in
controlled academic clinic settings limiting their external
validity, the paucity of purposeful collaborations between
academic researchers and practice staff throughout the
research process, the failure to assess practices’ needs
prior to developing and testing the intervention, and a
lack of consideration for the diverse practice contexts
[64]. However, as the healthcare system continues to
shift toward a value-based payment model, safety-net
practices will need to continue to transform their health-
care delivery systems to implement interventions at an
accelerated rate.
Our study protocol aims to address this critical need
by applying rigorous research methods to identify how
efficacious implementation strategies such as PF may
work to expedite the translation process for implement-
ing evidence-based practices into safety-net practices to
improve health outcomes in Latino patients with hyper-
tension, who suffer disproportionately from poor BP
control. Our study will also address critical questions
about individual, provider/staff-, and practice-level fac-
tors likely to influence the implementation of such ap-
proaches. Published reports often omit important details
about implementation fidelity, what type of training or
assistance practices need, and how these approaches fit
within the culture of the practice [16, 65–67]. To our
knowledge, this is one of the first studies that assesses
implementation fidelity as a multipronged measure to
elucidate how best to translate an efficacious interven-
tion into safety-net practices. Previous implementation
fidelity research has focused solely on calculating a sin-
gle fidelity score, determined almost exclusively by
measuring adherence to the study protocol [46]. Thus, a
large gap remains in our understanding of how and why
efficacious interventions may (or may not) be effective
when translated to real-world settings. Moreover, data
linking variation in clinical outcomes with variation in
organizational factors (e.g., adaptive reserve) are often
missing. Our use of a rigorous mixed methods approach
that examines the five core dimensions of implementa-
tion fidelity, as opposed to a singular construct, will
allow us to document and address any observed variabil-
ity in process and clinical outcomes across the practices.
Limitations
There are several methodological challenges that we
may encounter during the course of the study. First,
there are limitations to collecting our clinical outcome
data through the EHR. Data on medication adherence
(PDC metric) are based on prescription refill claims,
which may miss instances where patients pay out-of-
pocket for medications or where pharmacies fail to
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render claims for prescriptions they fill. This could result
in a PDC that appears lower than true adherence. We
estimate that 10% of patients would pay out-of-pocket
for their antihypertensive medications [68]. Another po-
tential limitation is that patients may refill their prescrip-
tions but not take the medication, resulting in a high
PDC but low adherence. To address these limitations,
we will collect information on patients who pay out-of-
pocket for their medications and ask patients to report
on their level adherence over the past month using a
well-validated self-report adherence scale [52, 53]. An-
other limitation is the potential variability in the meas-
urement of BP by different clinic staff. We will address
this by using the mean of the last two readings in the
EHR. Finally, changes in the external healthcare context
may affect implementation and clinical outcomes (e.g.,
changes in reimbursement for medications). We will col-
lect data on changes to the external healthcare context
throughout the study to account for any threats to in-
ternal validity in our analyses.
Implications
The goal of ALTA is to test PF as a strategy for accelerat-
ing the implementation of an evidence-based multi-level
intervention for improved hypertension management into
routine practice within “real world” safety-net primary
care settings. To facilitate sustainability, ALTA is designed
to complement other quality improvement initiatives cur-
rently underway at the practices such as Meaningful use,
Patient-Centered Medical Home, and attaining Healthcare
Effectiveness Data and Information Set [69] quality met-
rics, including BP control as well as supporting practices’
efforts to receive Nursing MAGNET status.
ALTA combines a rigorous research framework with a
mixed method approach to evaluate the effect of a tailored
PF strategy on the implementation process (fidelity) and
clinical-effectiveness (BP control, medication adherence)
of a multilevel approach to improving hypertension con-
trol in safety-net practices. By examining the barriers and
facilitators that affect the implementation of ALTA at
each level, our study will add knowledge that will increase
the generalizability of our findings to other safety-net
practices and guide effective scale-up across primary care
practices nationally. Moreover, the knowledge gained
from this study will provide key academic, community,
and policy stakeholders a practical and replicable strategy
for implementing efficacious interventions into routine
care that has potential for broad dissemination, ultimately
contributing to the reduction of health disparities seen in
racial and ethnic minority populations.
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